Document 0610
 DOCN  M9460610
 TI    Markers predicting progression of human immunodeficiency virus-related
       disease.
 DT    9404
 AU    Tsoukas CM; Bernard NF; McGill University AIDS Centre, Montreal, Quebec,
       Canada.
 SO    Clin Microbiol Rev. 1994 Jan;7(1):14-28. Unique Identifier : AIDSLINE
       MED/94163590
 AB    Human immunodeficiency virus (HIV) interacts with the immune system
       throughout the course of infection. For most of the disease process, HIV
       activates the immune system, and the degree of activation can be
       assessed by measuring serum levels of molecules such as beta
       2-microglobulin and neopterin, as well as other serum and cell surface
       phenotype markers. The levels of some of these markers correlate with
       clinical progression of HIV disease, and these markers may be useful as
       surrogate markers for development of clinical AIDS. Because the
       likelihood and timing of development of clinical AIDS following
       seroconversion, for any particular individual, are not readily
       predictable, the use of nonclinical disease markers has become
       critically important to patient management. Surrogate markers of HIV
       infection are, by definition, measurable traits that correlate with
       disease progression. An ideal marker should identify patients at highest
       risk of disease progression, provide information on how long an
       individual has been infected, help in staging HIV disease, predict
       development of opportunistic infections associated with AIDS, monitor
       the therapeutic efficacy of immunomodulating or antiviral treatments,
       and the easily quantifiable, reliable, clinically available, and
       affordable. This review examines the current state of knowledge and the
       role of surrogate markers in the natural history and treatment of HIV
       infection. The clinical usefulness of each marker is assessed with
       respect to the criteria outlined for the ideal surrogate marker for HIV
       disease progression.
 DE    Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/THERAPY  Antigen-Antibody
       Complex/BLOOD  Antigens, Surface/BLOOD/METABOLISM  *Biological Markers
       Human  HIV/*IMMUNOLOGY  HIV Antibodies/BLOOD  HIV Core Protein p24/BLOOD
       HIV Infections/*IMMUNOLOGY/THERAPY  T-Lymphocyte Subsets/IMMUNOLOGY
       JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).